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Genetics of COPD
Hidetoshi Nakamura1
ABSTRACT
Previous family studies suggested that genetic variation contributes to COPD susceptibility. The only gene
proven to influence COPD susceptibility is SERPINA1, encoding α1-antitrypsin. Most studies on COPD candi-
date genes except SERPINA1, have not been consistently replicated. However, longitudinal studies of decline
in lung function, meta-analyses of candidate gene studies, and family-based linkage analyses suggested that
variants in EPHX1, GST, MMP12, TGFB1, and SERPINE2 were associated with susceptibility to COPD. A
genome-wide association (GWA) study has recently demonstrated that CHRNA35 in 15q25 was associated
with COPD compared with control smokers. It was of interest that the CHRNA35 locus was associated with
nicotine dependence and lung cancer as well. The associations of HHIP on 4q31 and FAM13A on 4q22 with
COPD were also suggested in GWA studies. Another GWA study has shown that BICD1 in 12p11 was associ-
ated with the presence or absence of emphysema. Although every genetic study on COPD has some limita-
tions including heterogeneity in smoking behaviors and comorbidities, it has contributed to the progress in elu-
cidating the pathogenesis of COPD. Future studies will make us understand the mechanisms underlying the
polygenic disease, leading to the development of a specific treatment for each phenotype.
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INTRODUCTION
Cigarette smoking is the primary risk factor for the
development of chronic obstructive pulmonary dis-
ease (COPD). However, it is thought that only 15-20%
of smokers develop COPD. Previous family studies
suggested that genetic variation contributes to COPD
susceptibility. The only gene definitely proven to in-
fluence COPD susceptibility is SERPINA1, encoding
α1-antitrypsin.1 There have been many studies on
COPD candidate genes other than SERPINA1, but
most of them have not been consistently replicated.
This may be attributable to heterogeneity of the
study populations and COPD phenotypes. As hy-
potheses, different genes may contribute to mild,
moderate, or severe airflow limitation. Emphysema-
tous changes and airway wall thickness may be influ-
enced by distinct gene polymorphisms. Races and
gender2 are also known to effect on associations be-
tween genetic variation and COPD phenotypes.
Moreover, smoking habit is significantly regulated by
genetic factors,3 which can modify the outcomes of
genetic studies on COPD. COPD usually develops in
elderly patients with other coexistent disorders such
as lung cancer and cardiovascular diseases. These
disorders are also promoted by smoking and influ-
enced by distinctive genetic factors. All these find-
ings, not always stratified in previous studies, lead to
limitations of candidate gene approaches on COPD.
In this article, genetic studies of COPD including can-
didate gene studies, family-based linkage analyses,
and genome-wide association studies (GWAS) will be
reviewed. The author believes that genetic studies on
COPD contribute to understanding the pathogenesis
of the polygenic disease with multiple phenotypes de-
spite the difficulties described above.
CANDIDATE GENE STUDIES
α1-antitrypsin is a major circulating inhibitor of serine
proteases. Severe α1-antitrypsin deficiency usually re-
sults from a PiZZ or PiZnull genotype. This rare re-
cessive trait is commonly seen in individuals of
Northern European origin. About 1-2% of COPD pa-
tients were reported to be α1-antitrypsin deficiency in
the United States while there are only about 20 pedi-
grees with Siiyama genotype in Japan.4 Development
of panlobular emphysema and decline in lung func-
tion occur in both smokers and nonsmokers with the
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Table　1　Signifi cant genetic associations with decline in lung function
Candidate Gene (Gene Symbol) Polymorphism Reference
α1-antitrypsin (SERPINA1) MZ 6
MMP-1 (MMP1) -1607 + G 8
MMP-12 (MMP12) -82A/G 9
ADAM 33 (ADAM33) F + 1, S_1, etc 10
microsomal epoxide hydrolase (EPHX1) Tyr113 > His, Arg139 > His 6, 12
glutathione S-transferase (GST) GSTP1 Ile105 > Val 11, 19
heme oxygenase-1 (HMOX1) L-allele (≥33 GT repeats) 12, 20
glutamate cysteine ligase, catalytic subunit (GCLC) -129C/T 13
cytochrome P450 3A5 (CYP3A5) *1/*3 vs *3/*3 14
interleukin-1β (IL1B), interleukin-1 receptor antagonist (IL1RN) IL1B/IL1RN haplotypes 15
interleukin-4 receptor α (IL4RA) 551RR 16
interleukin-6 (IL6) -174G/C 17
β2-adrenergic receptor (ADRB2) Glu27 > Gln 18
ADAM, a disintegrin and metalloprotease.
Table　2　Signifi cant genetic associations with COPD sus-
ceptibility by a systemic review and meta-analysis of case-
control candidate gene studies
Candidate Gene 
(Gene Symbol)
Polymor-
phism
OR 
(95%CI)
glutathione S-transferase 
(GST)
GSTM1 null 
variant
1.45 
(1.09-1.92)
TGF-β1 (TGFB1) +29T/C 0.73 
(0.64-0.83)
TNF-α (TNF) -308G/A 1.19 
(1.01-1.40)
super oxide dismutase-3 
(SOD3)
R213G 1.97 
(1.24-3.13)
OR, odds ratio; CI, confi dence interval.
severe deficiency, although smoking increases the
risk accordingly. α1-antitrypsin deficiency accounts
for only a small part of COPD in the world, but it illus-
trates the interaction between genes and environ-
mental exposures and the differential contribution of
genetic factors to COPD susceptibility between differ-
ent ethnic groups.5
Since α1-antitrypsin deficiency was reported to
cause COPD, a lot of candidate gene association stud-
ies have been published. Candidate genes have been
selected in terms of putative pathogenesis of COPD
such as the protease-antiprotease imbalance, the oxi-
dative stress and antioxidants, and cytokines and
chemokines related to airway inflammation. Over 100
published COPD candidate gene studies suggested
each genetic variant’s contribution to one of COPD
phenotypes in the reported ethnic groups. However,
most of these findings have not been consistently rep-
licated as a result of the volume and heterogeneity of
the researches.
Sandford et al. have taken advantage of the Lung
Health Study to examine gene variants associated
with rapid decline in lung function.6 They selected
300 continued smokers with the most rapid decline
and 300 with the least rapid decline in FEV1 among
the approximately 6,000 individuals. They have tested
over 50 genes and those with altered risk for decline
in FEV1 are presented in Table 1.6-8,11,15-18 Other in-
vestigators have studied the same (microsomal epox-
ide hydrolase,12 glutathione S-transferase,19 heme
oxygenase-120) or additional genes (MMP-12,9
ADAM33,10 glutamate cystein ligase,13 CYP3A514) in
different cohorts of smokers in which longitudinal
lung function data are available (Table 1). Hunning-
hake et al. have recently tested for an association be-
tween single nucleotide polymorphisms (SNPs) in
the MMP-12 gene and lung function in more than
8,300 subjects in seven cohorts.9 The minor allele of a
SNP in MMP-12 was associated with a positive effect
on lung function in children with asthma and in
adults who smoke, and was associated with a reduced
risk of COPD in adult smokers during over 30 years
of follow-up. Association studies of genetic variants
with decline in lung function have reasonably sug-
gested the roles of several molecules related to
proteases-antiproteases imbalance, oxidative stress,
and cytokine-mediated inflammation in the develop-
ment of airflow limitation.
Castaldi et al. have recently conducted a systematic
review and meta-analysis of all population-based,
case-control candidate gene COPD studies before 16
July 2008.21 They identified 27 genetic variants with
adequate data for quantitative meta-analysis. Of these
variants, four (GST, TGFB1, TNF, SOD3 22) were sig-
nificantly associated with COPD susceptibility (Table
2). SOD3 encodes extracellular superoxide dismu-
tase, the most important extracellular scavenger of
superoxide. Although only two studies about the
SOD3 variant were included in the meta-analysis, Juul
et al. included over 9,000 individuals (978 COPD
Genetics of COPD
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Table　3　Candidate genes suggested by linkage analyses
Gene 
Symbol
Chromo-
some Phenotype
Study 
population
SERPINE2 2q33-35 FEV1/FVC Boston early-
onset COPD
TGFB1 19q13 pre-broncho-
dilator FEV1
Boston early-
onset COPD
SMOC2 6q27 FEV1 Framingham 
Study
Table　4　Candidate genes for COPD suggested by ge-
nome-wide association studies
Gene 
Symbol
Chromo-
some Phenotype
Study 
population
CHRNA3/5 15q25 COPD 
(%FEV1 < 80)
COPD vs con-
trol smoker
HHIP 4q31 COPD
 (%FEV1 < 80)
COPD vs con-
trol smoker
FAM13A 4q22 COPD 
(%FEV1 < 80)
COPD vs con-
trol smoker
BICD1 12p11 COPD with 
emphysema
COPD
cases and 7604 controls).22
LINKAGE ANALYSES
Family-based linkage analyses have brought us a
great advance in this field. Although COPD patients
are usually aged and linkage studies are basically dif-
ficult, the Boston early-onset COPD study recruited
relatively young (52 years) and severe patients
(FEV1 40% predicted) and their relatives (72 pedi-
grees and 560 family members).23 The study has sug-
gested the association of SERPINE2 in the chromo-
some 2q with FEV1FVC24 and TGFB1 in the chro-
mosome 19q with pre-bronchodilator FEV125 (Table
3). SERPINE2 encodes a 44-kDa cellular and extra-
cellular matrix-associated serine protease inhibitor,
mainly involved in coagulation and fibrinolysis. A
mechanism by which SERPINE2 may contribute to
the development of COPD has yet to be identified.
Framingham study has suggested that FEV1 was
linked to SMOC2 in the chromosome 6q27 in a gen-
eral population.26,27 SMOC2 encodes secreted modu-
lar calcium-binding protein 2, which has homology to
the protease inhibitor α1-antitrypsin and contains
multiple domains with the potential to act as protease
inhibitors. These observations obtained from linkage
analyses are thought to be more reliable for the de-
tection of susceptibility genes for COPD than those in
case-control candidate gene studies. However, differ-
ences in study populations and target phenotypes
should be noted in these analyses as well. It was not
surprising that the genes identified in the Boston
early-onset COPD study were different from those in
the Framingham study since the former represented
one of the severest subpopulations of COPD while
the latter might represent subjects with relative air-
flow limitations in the general population. In general
it is difficult to find disease susceptibility genes by
linkage analyses because of relatively small numbers
of microsatellite markers (300-400).
GENOME-WIDE ASSOCIATION STUDIES
GWAS require hundreds or thousands of participants
genotyped in 300,000-500,000 SNP markers. Recent
advances in genetical analyses have enabled us to
conduct GWAS in COPD. Pillai et al. have demon-
strated that 2 SNPs at CHRNA35 in 15q25 were as-
sociated with COPD (n = 823) when compared with
control smokers (n = 810).28 This finding was repli-
cated by the other case-control populations and
family-based association analyses. CHRNA35 en-
codes nicotinic cholinergic receptor alpha 3, 5, known
to be associated with nicotine addiction and lung can-
cer.29,30 The association of HHIP locus on 4q31 was
also consistently replicated but did not reach
genome-wide significance levels. HHIP encodes
hedgehog interacting protein, belonging to the
hedgehog gene family that play an important role in
regulating morphogenesis and lung development.28
Cho et al. have reported that variants in FAM13A are
associated with COPD by increasing the numbers of
participants (2940 cases and 1380 smoking con-
trols).31 FAM13A encodes family with sequence simi-
larity 13, member A. While little is known about FAM
13A function, gene expression analyses in cell lines
have demonstrated a consistent increase in response
to hypoxia. Differences in respiratory epithelial cell
expression of FAM13A have been noted during dif-
ferentiation into pulmonary type II cells in vitro.32
Kong et al. has reported that a SNP in BICD1 was as-
sociated with the presence or absence of emphysema
in GWAS. They divided 2380 COPD patients from the
Norway, ECLIPSE, and NETT into those with or
without emphysema by chest-CT analyses (Table
4).33 BICD1 encodes bicaudal D homolog 1 (Droso-
phila). BICD protein forms a complex with dynein-
dynactin and plays a role in mediating dynein func-
tion. SNPs in BICD1 gene have been associated with
telomere length in leukocytes.34 Association among
variants in BICD1, telomere length, and emphysema
is expected to be investigated.
More genes including HHIP and FAM13A have
been reported to be associated with lung function in
GWAS in general populations (Table 5).35-37 PTCH1
is known to encode a membrane receptor of hedge-
hog protein including HHIP. Thus the variants in
HHIP and PTCH1 may influence lung development
possibly related to COPD phenotypes.37 In contrast
AGER is highly expressed in the lung and its absence
contributes to the pathogenesis of idiopathic pulmo-
nary fibrosis. Since AGER signaling is involved in
host defense, inflammation, and tissue remodeling,
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Table　5　Candidate genes for lung function suggested by
genome-wide association studies in general populations
Gene 
Symbol
Chromo-
some Phenotype Reference
IL6R 1q23 FEF25-75 35
TNS1 2q35 FEV1 36
PID1 2q36 FEV1/FVC 37
FAM13A 4q22 FEV1/FVC 37
GSTCD 4q24 FEV1 36, 37
HHIP 4q31 FEV1/FVC 36, 37
HTR4/
ADAM19
5q33 FEV1, FEV1/FVC 36, 37
AGER 6p21 FEV1/FVC 36, 37
GPR126 6q24 FEV1/FVC 37
PTCH1 9q22 FEV1/FVC 37
THSD4 15q23 FEV1/FVC 36
Table　6　Candidate genes associated with smoking behav-
iors and COPD
Gene 
Symbol
Chromo-
some Polymorphism Reference
CHRNA3/5 15q25 SNP (rs1051730) 3, 30
CYP2A6 19q13 *4 39
SLC6A4 17q11 SNP (rs2020936) 41
variants in AGER may be relevant to the development
of COPD.37 Further information on molecular func-
tions of the candidate genes associated with lung
function is available in the references.35-37 GWAS can
theoretically pick up phenotype-specific gene poly-
morphisms though they still have similar limitations
in selecting COPD and control populations to candi-
date gene case-control studies. In addition the com-
monly used multistage GWA approach, using very
stringent P values in the identification cohort, might
result in missing relevant findings that do not show
genome-wide significance.38
GENETICS OF SMOKING BEHAVIORS
A number of linkage analyses have suggested that
the specific loci influence smoking behaviors includ-
ing age at initiation, intensity (number of cigarettes
smoked per day), and cessation.3 GWAS of cigarette
smoking behaviors have suggested that CHRNA35
in 15q25 was associated with smoking intensity and
nicotine dependence.3,30 This locus was identified not
only as that for COPD28 but also for lung cancer29 by
GWAS although it is unclear whether the effects of
these variants on susceptibility to COPD and lung
cancer are due to their influences on smoking behav-
iors. A genotype-environmental interaction is defined
as a non-additive contribution of genetic and environ-
mental factors to the expression of a phenotype.5
Therefore independent contributions of genetic fac-
tors and smoking to COPD are very difficult to be
evaluated since the environmental factors can be
regulated by the same andor different genetic fac-
tors asfrom those for COPD.
Minematsu et al. have reported that the deletion
polymorphism of CYP2A6, a major nicotine metabo-
lizing enzyme, was associated with smoking intensity
and development of emphysema after normalizing
lifelong cigarette consumption (Table 6).39 Defective
alleles of CYP2A6 were also reported to reduce the
risk of lung cancer partly independent of their effects
on smoking behaviors.40 These observations are
thought to be related to its function to activate procar-
cinogens including nitrosamines. Ishii et al. have re-
cently reported the association of a SNP in SLC6A4,
encoding 5-hydroxytryptamine transporter, related to
nicotine dependence with COPD which partly de-
pends on tobacco consumption. They also suggested
the association of another SNP with a depression
score.41 The numbers of participants of these Japa-
nese studies are relatively small, but they are of inter-
est that susceptibility to COPD is potentially influ-
enced by genetic factors related to smoking habits
other than CHRNA35. Although COPD is known to
develop only in part of smokers, it is also true that
heavy smokers tend to become COPD. Therefore the
factors that increase smoking intensity may overlap
those for COPD. Further systematic genetic studies
will be necessary to elucidate the relationship be-
tween genetic variants related to smoking behaviors
and COPD.
FUTURE PERSPECTIVES
Genetic studies of COPD had started as candidate
gene case-control studies. After a couple of family-
based linkage analyses were reported, GWAS have
recently been applied to identify novel genetic vari-
ants associated with COPD. GWAS are hypothesis
free, and functional assessment of identified genetic
variants is inevitable. Even in GWAS, heterogeneity
of study populations is the biggest problem that can
result in distinct outcomes. Environmental factors in-
cluding smoking status and air pollution should care-
fully be taken into account. As a target phenotype,
emphysema has already been used in a GWA study,33
but criteria to judge the presence or absence of em-
physema on chest-CT analysis are not yet estab-
lished. Since perfect matching of COPD cases and
control smokers populations is impossible, other
genomic approaches should be considered as well.
DeMeo et al. have utilized genomic regions from 56
lung-tissue gene-expression microarrays to select 889
SNPs to be tested for association with COPD, and
concluded that IREB2 near the CHRNA35 locus was
associated with COPD.42 IREB2 encodes iron-
responsive element binding protein 2 that is an RNA
binding protein involved in maintaining human cellu-
lar iron metabolism. IREB2 mRNA expression was in-
Genetics of COPD
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creased in lung tissues from COPD patients than
those from normal subjects. Whole-genome gene ex-
pression studies are useful in understanding the
pathogenesis of COPD and selecting candidate genes
for genetical studies.
Since most COPD patients are elderly with comor-
bidities such as asthma, lung cancer, hypertension,
cardiovascular diseases, diabetes mellitus, etc., it will
be important to stratify these coexistent diseases in
future genetical studies of COPD. Regan et al. have
stated that they will enroll 10,000 smokers between
ages of 45 and 80 years and exclusion criteria are a
history of other lung disease except asthma (e.g. pul-
monary fibrosis, extensive bronchiectasis, cystic fi-
brosis), active cancer under treatment, lung cancer,
myocardial infarction, other cardiac hospitalization,
etc. in the Genetic Epidemiology of COPD (COP-
DGene) study design.43 These criteria may be rea-
sonable but it is difficult to find best criteria to ana-
lyze genetic factors of COPD patients with comorbidi-
ties. Race and gender have been clearly defined in
the COPDGene study. To define the phenotypes CT-
images will be obtained both on inspiratory and expi-
ratory phases in addition to spirometry in this study.
Recent studies have suggested novel mechanisms
underlying the pathogenesis of COPD such as apop-
tosis and senescence of lung cells, activated autoim-
mune processes,44 chronic airway infection, epige-
netic regulation such as modifications of histon
deacetylases (HDACs),45 and impaired lung develop-
ment.46 All these mechanisms will provide us infor-
mation about additional candidate gene approaches
and functional analyses of novel gene variants. Ge-
netic studies of COPD have confirmed the hypothe-
ses of the disease mechanisms such as protease-
antiprotease imbalance and excessive oxidative
stress, and will further make sure the novel mecha-
nisms described above. One of the most important
purposes of genetical studies of COPD is a clinical ap-
plication of pharmacogenetics. However, few COPD
pharmacogenetics studies have been performed.
Most studies have examined the role of variants in
the β2-adrenergic receptor gene in bronchodilator re-
sponse, but the findings were inconclusive.47 In fu-
ture, personalized treatment of specific phenotypes of
COPD based on pharmacogenetics studies will be ex-
pected including existing COPD therapies such as
long-acting β-agonists and muscarinic antagonists,
and smoking cessation therapy.
Although every genetic study on COPD has some
limitations and should be carefully interpreted, we be-
lieve that it has greatly contributed to the progress in
elucidating the pathogenesis of COPD. Future stud-
ies will bring us insight into mechanisms underlying
various phenotypes of COPD including emphysema,
pulmonary hypertension, and mucus secretion, lead-
ing to the development of a specific treatment for
each disease process.
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